Sawai Group HoldingsSAWAI GROUP HOLDINGS Co., Ltd.4887東証プライム医薬品FY ending Mar 2026, consolidated, IFRS
About 82% of Sawai Group Holdings's sales come from Japan, with USA making up much of the rest.
Out of every ¥100 of sales, about ¥10 is left as operating profit.
Revenue changed -15.5% from the prior year.
FY ending Mar 2022 → FY ending Mar 2023
FY ending Mar 2022 → FY ending Mar 2023
※ Segment revenues include inter-segment sales and are scaled to consolidated revenue
For every ¥100 Sawai Group Holdings sells, how much goes where, and how much is kept.
Aligned fiscal years compare the shares of revenue remaining as gross, core, and net profit. Missing years are left unconnected.
Revenue by business segment, and the profit each one keeps.
※ Segment figures include inter-segment sales and do not sum to the company total
EDINET (FSA Japan)
有価証券報告書－第5期(2025/04/01－2026/03/31)
EDINET (FSA Japan)
有価証券報告書－第4期(2024/04/01－2025/03/31)
EDINET (FSA Japan)
有価証券報告書－第3期(2023/04/01－2024/03/31)
EDINET (FSA Japan)
有価証券報告書－第2期(2022/04/01－2023/03/31)
Extracted from XBRL: 44 / Derived from other figures: 1
Spotted an error? Report it (corrections keep the original record)
Markdown with figures, units, periods and sources, ready to paste into ChatGPT or Claude.